Parkinson’s drug trial offers glimmer of hope for brain cells

LONDON, Feb 27 (Reuters) – An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease.

The trial involved delivery of a protein therapy directly into the brains of Parkinson’s patients. Scientists said some brain scans revealed “extremely promising” effects on damaged neurons of those who received the treatment.

“The spatial and relative magnitude of the improvement in the brain scans is beyond anything seen previously in trials,” said Alan Whone, a Parkinson’s specialist at Britain’s Bristol University who co-led the trial.

Researchers said the therapy warranted further investigation even though it failed to demonstrate improvement of symptoms in patients who received it when compared to others given a placebo.

“The primary outcome was disappointing,” Whone told reporters at a briefing in London.

Parkinson’s is a neurodegenerative disease that affects around one percent to two percent of people over age 65. It causes tremors, muscle stiffness and movement and balance problems. Although some medicines can improve symptoms, there is no cure or treatment that can slow progression of the disease.

This trial involved 41 patients who all underwent robot-assisted surgery to have tubes placed into their brains.

That allowed doctors to infuse either the experimental treatment – called Glial Cell Line Derived Neurotrophic Factor (GDNF) – or a placebo directly to the affected brain areas. GDNF is made by privately-held Canadian biotech firm MedGenesis Therapeutix.

Half of the patients were given monthly GDNF infusions and half received monthly placebo infusions. After nine months, all participants were offered the GDNF infusions for a further nine months.

Results showed some signs of improvements, Whone said, but there was no significant difference between the treatment and placebo groups. He said this was in part due to the sizeable placebo effect in this trial.

The placebo effect has been known to confound clinical trials of treatments for conditions involving the brain, boosted by patients’ expectations that a potential treatment will work.

But the brain scan results suggested the drug might be starting to reawaken damaged brain cells. After nine months, there was no change in the scans of patients who received a placebo, but those who got GDNF showed major changes in a key area of the brain affected by the disease.

Whone said this suggested GDNF could be “a means to possibly reawaken and restore” brain cells that are gradually destroyed in Parkinson’s.

Source

more recommended stories

  • Senator Gillibrand wants insurance to pay for fertility treatments

    WASHINGTON (Reuters) – U.S. Democratic presidential.

  • Hundreds rally at U.S. Supreme Court, calling state abortion bans as step backward

    WASHINGTON (Reuters) – Abortion-rights campaigners, including.

  • French court says doctors must resume life support for paralyzed patient

    STRASBOURG, France (Reuters) – A French.

  • Missouri follows Alabama by passing restrictive abortion bill

    (Reuters) – Missouri lawmakers passed a.

  • Too much screen time tied to school problems even in little kids

    (Reuters Health) – Kindergarteners who get.

  • Smokers have higher risk for multiple strokes

    (Reuters Health) – Smokers who have.

  • Missouri assembly passes restrictive abortion bill, days after Alabama

    (Reuters) – The lower house of.

  • Missouri Senate passes bill to ban abortions after eight weeks

    (Reuters) – Missouri’s Senate passed a.

  • Alabama governor signs strictest U.S. abortion ban into law

    (Reuters) – Alabama’s governor signed a.

  • Alabama Senate bans nearly all abortions, including rape cases

    (Reuters) – Alabama’s state Senate passed.

  • Israel regulator warns of medical cannabis bubble, eyes Australia pact

    JERUSALEM (Reuters) – Medical cannabis could.

  • U.S. measles outbreak grows with 75 new cases, mostly in New York

    (Reuters) – U.S. health authorities recorded.

  • Teva Pharm CFO says company did not conspire to fix prices

    FILE PHOTO: The logo of Teva.

  • U.S. states accuse Teva, other drugmakers, of price-fixing: lawsuit

    WASHINGTON (Reuters) – U.S. states filed.

  • Exclusive: Philip Morris suspends social media campaign after Reuters exposes young ‘influencers’

    (Reuters) – Cigarette maker Philip Morris.

  • Hong Kong reports African swine fever case

    HONG KONG (Reuters) – Hong Kong.

  • Alabama Senate delays vote on strict anti-abortion bill

    (Reuters) – Alabama’s state Senate on.

  • Denver votes to become first U.S. city to decriminalize ‘magic mushrooms’

    Psilocybin or “magic mushrooms” are seen.

  • AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

    The company logo for pharmaceutical company.

  • Denver to vote on decriminalizing ‘magic mushrooms’

    FILE PHOTO: Boxes containing magic mushrooms.

  • Trans teens face higher sexual assault risk when schools restrict bathrooms

    (Reuters Health) – Transgender adolescents may.

  • U.S. doctors use medical records to fight measles outbreak

    CHICAGO (Reuters) – U.S. doctors are.

  • UK’s Vectura wins patent infringement case against GlaxoSmithKline in U.S

    (Reuters) – British drugmaker Vectura Group.

  • Tyson Foods recalls almost 12 million pounds of chicken strips over contamination fears

    (Reuters) – Tyson Foods Inc significantly.

  • Monstrous rumors stoke hostility to Pakistan’s anti-polio drive

    PESHAWAR, Pakistan (Reuters) – His bearded.

  • U.S. health agency finalizes conscience and religious freedom rule

    WASHINGTON (Reuters) – The U.S. Department.

  • Medication use drops when local drugstores close

    (Reuters Health) – People are less.

  • EPA says popular weed killer glyphosate is not a carcinogen

    CHICAGO (Reuters) – The U.S. Environmental.

  • Novartis’s Sandoz strikes deal for biosimilar of Herceptin

    FILE PHOTO: Swiss drugmaker Novartis’ logo.

  • U.S. measles outbreak triggers quarantine at two Los Angeles universities

    LOS ANGELES (Reuters) – A nationwide.

  • U.S. measles outbreak raises questions about immunity in adults

    (Reuters) – Adults in the United.

  • FDA approves expanded label for Regeneron/Sanofi’s cholesterol drug

    (Reuters) – The U.S. Food and.